180 related articles for article (PubMed ID: 35909902)
1. A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
Shao C; Chang MS; Lam FC; Marley AR; Tang H; Song Y; Miller C; Brown M; Wan I; Han J; Adeboyeje G
J Oncol; 2022; 2022():5830475. PubMed ID: 35909902
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract][Full Text] [Related]
3. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
4. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
5. Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.
Shao C; Ren Y; Zhou H; Lee LC; Chen C; Dettman EJ; Cristescu R; Gozman A; Jin F; Zhou W
Adv Ther; 2024 Feb; 41(2):759-776. PubMed ID: 38169059
[TBL] [Abstract][Full Text] [Related]
6. Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors.
Shao C; Ren Y; Zhou H; Chen C; Dettman EJ; Lee LC; Cristescu R; Gozman A; Jin F; Zhou W
JCO Precis Oncol; 2023 Sep; 7():e2300195. PubMed ID: 37972338
[TBL] [Abstract][Full Text] [Related]
7. Homologous Recombination Abnormalities Associated With
Albitar M; Zhang H; Pecora A; Waintraub S; Graham D; Hellmann M; McNamara D; Charifa A; De Dios I; Ma W; Goy A
Breast Cancer (Auckl); 2023; 17():11782234231198979. PubMed ID: 37789896
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
9. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Koole SN; Schouten PC; Hauke J; Kluin RJC; Nederlof P; Richters LK; Krebsbach G; Sikorska K; Alkemade M; Opdam M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; Mom CH; Arts HJG; van Ham M; van Dam P; Vuylsteke P; Sanders J; Horlings HM; van de Vijver KK; Hahnen E; van Driel WJ; Schmutzler R; Sonke GS; Linn SC
Int J Cancer; 2022 Oct; 151(8):1394-1404. PubMed ID: 35583992
[TBL] [Abstract][Full Text] [Related]
10. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
11. Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
Sayyid RK; Klaassen Z; Berlin A; Roy S; Brandão LR; Bernardino R; Chavarriaga J; Jiang DM; Spratt DE; Fleshner NE; Wallis CJD
BJU Int; 2023 Dec; 132(6):619-630. PubMed ID: 37461140
[TBL] [Abstract][Full Text] [Related]
12. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
14. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract][Full Text] [Related]
16. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
[TBL] [Abstract][Full Text] [Related]
17. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
[TBL] [Abstract][Full Text] [Related]
18. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
20. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
